Morgan Keegan Leaves Ventas Outperform, $60 PT Unchanged (VTR)

Morgan Keegan left its Ventas VTR Outperform rating and $60 price target unchanged in a research report published today. In the report, Morgan Keegan states, "We expect the company to report that its fourth quarter acquisition was dominated by three already-announced transactions: the pending $3.1 billion acquisition of Atria Senior Living, the $186 million acquisition of the remaining interest of 58 Sunrise facilities, and the $38 million acquisition of five medical office buildings by its Lillibridge subsidiary. In addition, we have updated our model to reflect last week's 5,563,000 share offering." Shares of Ventas were at $53.70 in after hours trading at the time of posting, reflecting no change from Friday's market close.